| Ytd | -27.54% | |
| 1y | 3.44% |
| Open | 1.40 | Prev Close | 1.40 | Low | 1.33 | High | 1.44 | Mkt Cap | 421.18M |
| Vol | 6.08M | Avg Vol | 6.71M | EPS | -0.41 | P/E | N/A | Forward P/E | -2.84 |
| Beta | 2.01 | Short Ratio | 4.46 | Inst. Own | 84.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.41 | 200-d Avg | 1.65 | 1yr Est | 3.02 |
PACB News
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced posi
Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, inclu
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to of
Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 reven
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Pacific Biosciences of California NASDAQ: PACB reported second-quarter 2026 revenue of $39 million,
On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuri
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.14 per share in line w
Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million
Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of hi
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the an
MENLO PARK, Calif. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASD
MENLO PARK, Calif. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financi
Vega SPRQ-Nx chemistry to deliver up to 90 Gb per run at 40% lower cost per gigabase, with single-sh
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs,
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) has been assigned a consens
Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, ref
MENLO PARK, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of
Amova Asset Management Americas Inc. cut its position in shares of Pacific Biosciences of California
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.36, indica
MENLO PARK, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it
On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50
Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level predict
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
The protocol will be formally presented at the upcoming American Association for Cancer Research (AA
Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to U
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today ann
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, ann
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and
Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral
Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overw
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
